Spravato
Spravato (esketamine), is a Schedule III controlled substance that was approved by FDA in 2019 as a rapidly-acting nasal spray for treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, in conjunction with an oral antidepressant.
Patients must be monitored after administration at In Step for a minimum of two hours, or until such time that patients are safe to leave with a driver with which they have pre-arranged to take them to and from the clinic.
Patients must be monitored after administration at In Step for a minimum of two hours, or until such time that patients are safe to leave with a driver with which they have pre-arranged to take them to and from the clinic.
